Cytokinetics, Inc.
Cytokinetics Announces Enrollment Open for CEDAR-HCM Pediatric Clinical Trial
Summary
On May 8, 2024, Cytokinetics, Incorporated announced the opening of enrollment for the CEDAR-HCM clinical trial. This trial, focusing on aficamten, a cardiac myosin inhibitor, aims to evaluate its efficacy, pharmacokinetics, and safety in pediatric patients aged 12 to 17 with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The primary endpoint of the trial is the change in Valsalva left ventricular outflow tract gradient (LVOT-G) from baseline to Week 12. Patients will be randomized to receive aficamten or placebo, with potential dose escalations based on specific criteria. The trial is expected to enroll approximately 40 adolescent patients initially, with a potential second cohort for younger patients aged 6 to 11.
Profitelligence Alerts
Get alerts for CYTK
Be first to know when Cytokinetics, Inc. files with the SEC.
Filing Categories
Advertisement
About Cytokinetics, Inc.
Cytokinetics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel muscle activators as potential treatments for debilitating diseases. Primarily, the company's work aims to address unmet medical needs in the fields of neurology and cardiology, offering therapeutic solutions that target muscle function. Cytokinetics' research centers on small molecule drugs that modulate muscle performance, which could significantly aid patients suffering from heart failure, amyotrophic lateral sclerosis (ALS), and other muscle-related conditions. The company is actively involved in clinical trials and collaborates with other notable entities in its quest for innovative medical advancements. Its contributions to the healthcare sector exemplify the growing role of targeted therapy in improving patient outcomes. Headquartered in South San Francisco, California, Cytokinetics operates as a key player in the biotechnology landscape, with a commitment to pioneering treatments that leverage the complex mechanisms of muscle biology.
Official SEC Documents
Advertisement